Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Activating and resistance mutations in tyrosine kinase domains of oncogenes are common in non-small cell lung cancer (NSCLC).
• Understanding the spectrum and abundance of these mutations is crucial for targeted therapy and patient stratification.

Purpose of the Study:

• To assess the frequency, type, and abundance of key oncogenic mutations (EGFR, KRAS, BRAF, TP53, ALK) in NSCLC.
• To evaluate the performance of the Single Molecule Amplification and Re-sequencing Technology (SMART) assay for mutation detection.
• To explore the clinical implications of personalized mutation profiling in NSCLC patient management.

Main Methods:

• Analysis of tumour specimens from 184 early and late-stage NSCLC patients.
• Utilized Single Molecule Amplification and Re-sequencing Technology (SMART) for comprehensive mutation profiling.
• Benchmarked SMART assay sensitivity and specificity against the gold standard ARMS-PCR for EGFR mutation detection.

Main Results:

• EGFR mutations were most prevalent (59.9%), followed by KRAS (16.9%), TP53 (12.7%), EML4-ALK fusions (6.3%), and BRAF (4.2%).
• SMART assay demonstrated high sensitivity (≥0.1%) and specificity (98.7%) for EGFR mutations.
• Tumour mutation profiles were heterogeneous, with monoclonal (51.6%) and polyclonal (12.6%) events observed; patterns were similar across early and advanced stages.

Conclusions:

• Personalized profiling and quantitation of oncogenic mutations in NSCLC are feasible and informative.
• This approach can enhance patient classification based on tumour characteristics.
• Ancillary information from mutation profiling can significantly aid clinicians in treatment decision-making for NSCLC.